BioXcel Therapeutics Net Worth
BioXcel Therapeutics Net Worth Breakdown | BTAI |
BioXcel Therapeutics Net Worth Analysis
BioXcel Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioXcel Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioXcel Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioXcel Therapeutics' net worth analysis. One common approach is to calculate BioXcel Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioXcel Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioXcel Therapeutics' net worth. This approach calculates the present value of BioXcel Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioXcel Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioXcel Therapeutics' net worth. This involves comparing BioXcel Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioXcel Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if BioXcel Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioXcel Therapeutics' net worth research are outlined below:
| BioXcel Therapeutics generated a negative expected return over the last 90 days | |
| BioXcel Therapeutics has high historical volatility and very poor performance | |
| BioXcel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.38 M. Net Loss for the year was (179.05 M) with profit before overhead, payroll, taxes, and interest of 251 K. | |
| BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioXcel Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Rodman Renshaw Initiates Coverage of BioXcel Therapeutics with Buy Recommendation - Nasdaq |
BioXcel Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioXcel Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioXcel Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
BioXcel Therapeutics Target Price Consensus
BioXcel target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. BioXcel Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Buy |
Most BioXcel analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand BioXcel stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of BioXcel Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBioXcel Therapeutics Target Price Projection
BioXcel Therapeutics' current and average target prices are 2.33 and 2.81, respectively. The current price of BioXcel Therapeutics is the price at which BioXcel Therapeutics is currently trading. On the other hand, BioXcel Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
BioXcel Therapeutics Market Quote on 21st of March 2025
Target Price
Analyst Consensus On BioXcel Therapeutics Target Price
Know BioXcel Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioXcel Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioXcel Therapeutics backward and forwards among themselves. BioXcel Therapeutics' institutional investor refers to the entity that pools money to purchase BioXcel Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arete Wealth Advisors, Llc | 2024-09-30 | 40.5 K | Diversify Wealth Management, Llc | 2024-12-31 | 40 K | Hennion & Walsh Asset Management Inc | 2024-12-31 | 39.4 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 38 K | Susquehanna International Group, Llp | 2024-09-30 | 34.2 K | Group One Trading, Lp | 2024-09-30 | 30.2 K | Squarepoint Ops Llc | 2024-09-30 | 23.7 K | Lpl Financial Corp | 2024-09-30 | 17.5 K | Point72 Asia (singapore) Pte. Ltd | 2024-09-30 | 15.2 K | Blackrock Inc | 2024-12-31 | 380.6 K | Geode Capital Management, Llc | 2024-09-30 | 298 K |
Follow BioXcel Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.01 M.Market Cap |
|
Project BioXcel Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.19) | (2.30) | |
| Return On Capital Employed | (4.25) | (4.04) | |
| Return On Assets | (2.19) | (2.30) | |
| Return On Equity | 3.64 | 3.83 |
When accessing BioXcel Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioXcel Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioXcel Therapeutics' profitability and make more informed investment decisions.
Evaluate BioXcel Therapeutics' management efficiency
BioXcel Therapeutics has return on total asset (ROA) of (0.6212) % which means that it has lost $0.6212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.6694) %, meaning that it created substantial loss on money invested by shareholders. BioXcel Therapeutics' management efficiency ratios could be used to measure how well BioXcel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The BioXcel Therapeutics' current Return On Equity is estimated to increase to 3.83, while Return On Tangible Assets are projected to decrease to (2.30). As of now, BioXcel Therapeutics' Non Current Assets Total are increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.30, while Non Currrent Assets Other are projected to decrease to under 95 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.75) | (1.66) | |
| Tangible Book Value Per Share | (1.75) | (1.66) | |
| Enterprise Value Over EBITDA | (7.68) | (8.06) | |
| Price Book Value Ratio | (21.90) | (22.99) | |
| Enterprise Value Multiple | (7.68) | (8.06) | |
| Price Fair Value | (21.90) | (22.99) | |
| Enterprise Value | 7.5 B | 5.6 B |
Evaluating the management effectiveness of BioXcel Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BioXcel Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 31.9094 | Revenue | Quarterly Revenue Growth (0.37) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioXcel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioXcel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioXcel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioXcel Therapeutics Corporate Filings
8K | 21st of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 4th of March 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify |
BioXcel Therapeutics Earnings Estimation Breakdown
The calculation of BioXcel Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BioXcel Therapeutics is estimated to be -6.331675 with the future projection ranging from a low of -6.8 to a high of -5.92. Please be aware that this consensus of annual earnings estimates for BioXcel Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-6.8 Lowest | Expected EPS | -5.92 Highest |
BioXcel Therapeutics Earnings Projection Consensus
Suppose the current estimates of BioXcel Therapeutics' value are higher than the current market price of the BioXcel Therapeutics stock. In this case, investors may conclude that BioXcel Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and BioXcel Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 4 | 71.6% | -0.32 | -6.331675 | -32.64 |
BioXcel Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of BioXcel Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering BioXcel Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of BioXcel Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.BioXcel Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as BioXcel Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of BioXcel Therapeutics should always be considered in relation to other companies to make a more educated investment decision.BioXcel Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact BioXcel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.54 | -0.32 | 0.22 | 40 | ||
2024-08-06 | 2024-06-30 | -0.71 | -0.21 | 0.5 | 70 | ||
2024-05-09 | 2024-03-31 | -0.7 | -0.87 | -0.17 | 24 | ||
2024-03-12 | 2023-12-31 | -0.91 | -0.76 | 0.15 | 16 | ||
2023-11-14 | 2023-09-30 | -1.3 | -1.72 | -0.42 | 32 | ||
2023-08-14 | 2023-06-30 | -1.75 | -1.83 | -0.08 | 4 | ||
2023-05-08 | 2023-03-31 | -1.62 | -1.84 | -0.22 | 13 | ||
2023-03-09 | 2022-12-31 | -1.45 | -1.95 | -0.5 | 34 | ||
2022-11-10 | 2022-09-30 | -1.35 | -1.49 | -0.14 | 10 | ||
2022-08-09 | 2022-06-30 | -1.22 | -1.35 | -0.13 | 10 | ||
2022-05-09 | 2022-03-31 | -1.15 | -1.12 | 0.03 | 2 | ||
2022-03-10 | 2021-12-31 | -1.1 | -0.93 | 0.17 | 15 | ||
2021-11-10 | 2021-09-30 | -1.05 | -0.96 | 0.09 | 8 | ||
2021-08-10 | 2021-06-30 | -1.08 | -1.11 | -0.03 | 2 | ||
2021-05-10 | 2021-03-31 | -0.94 | -1.08 | -0.14 | 14 | ||
2021-03-11 | 2020-12-31 | -0.96 | -0.87 | 0.09 | 9 | ||
2020-11-12 | 2020-09-30 | -0.8 | -1.07 | -0.27 | 33 | ||
2020-08-14 | 2020-06-30 | -0.75 | -1.06 | -0.31 | 41 | ||
2020-05-12 | 2020-03-31 | -0.59 | -0.79 | -0.2 | 33 | ||
2020-03-09 | 2019-12-31 | -0.63 | -0.45 | 0.18 | 28 | ||
2019-11-14 | 2019-09-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2019-08-06 | 2019-06-30 | -0.6 | -0.54 | 0.06 | 10 | ||
2019-05-07 | 2019-03-31 | -0.55 | -0.46 | 0.09 | 16 | ||
2019-03-07 | 2018-12-31 | -0.39 | -0.46 | -0.07 | 17 | ||
2018-11-09 | 2018-09-30 | -0.29 | -0.31 | -0.02 | 6 | ||
2018-08-08 | 2018-06-30 | -0.32 | -0.19 | 0.13 | 40 | ||
2018-05-14 | 2018-03-31 | -0.25 | -0.37 | -0.12 | 48 | ||
2018-03-12 | 2017-12-31 | 0 | -0.06 | -0.06 | 0 | ||
2017-11-13 | 2017-09-30 | 0 | -0.07 | -0.07 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -0.06 | -0.06 | 0 |
BioXcel Therapeutics Corporate Management
| Javier JD | Chief VP | Profile | |
| Frank Yocca | Chief Scientific Officer | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Javier Rodriguez | Chief VP | Profile | |
| Cedric Burg | VP Management | Profile | |
| Robert Scala | Vice Planning | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (32.64) | Revenue Per Share | Quarterly Revenue Growth (0.37) | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.